Anastrozole 1 mg

Anastrozole 1 mg contains the aromatase inhibitor anastrozole. In clinical medicine, it is approved for treatment of hormone receptor-positive breast cancer in postmenopausal women. In non-medical bodybuilding contexts, it is commonly referenced for managing estrogenic side effects from aromatizing anabolic steroids, though such use falls outside approved indications.

The standard clinical dose is one 1 mg tablet taken once daily for breast cancer treatment. In non-medical contexts, anastrozole is commonly referenced at lower doses of 0.25–1 mg every other day or twice weekly. These non-medical practices are not derived from controlled clinical trials for performance enhancement.

Anastrozole is an aromatase inhibitor, not an anabolic steroid, and does not suppress endogenous testosterone production. Post-cycle therapy is not applicable to anastrozole in the context of hormonal recovery. In non-medical settings, PCT protocols typically involve Clomiphene or Tamoxifen rather than anastrozole.

Anastrozole inhibits the aromatase enzyme (CYP19A1), which converts androgens into estrogens in peripheral tissues. By blocking this conversion, it reduces circulating estrogen levels. This mechanism underlies its clinical use in hormone receptor-positive breast cancer and its non-medical use for managing estrogenic side effects.

Anastrozole has an elimination half-life of approximately 30 to 60 hours, and steady-state plasma concentrations are typically reached within 7 days of daily administration. Estrogen suppression begins rapidly after the first dose, though clinical effects on hormone levels may take several days to fully manifest.

There is no universally established "best" aromatase inhibitor, and each has distinct characteristics. Anastrozole is a non-steroidal AI with high selectivity for the aromatase enzyme. Other AIs such as exemestane (steroidal) and letrozole (non-steroidal) have different mechanisms and potency profiles.

Anastrozole and Exemestane are both aromatase inhibitors but differ in type. Anastrozole is a non-steroidal, reversible inhibitor, while exemestane is a steroidal, irreversible (suicide) inhibitor. They have different potency profiles and side effect characteristics.

Anastrozole and Letrobol (letrozole) are both non-steroidal aromatase inhibitors. Letrozole is generally considered more potent at suppressing estrogen, while anastrozole has a broader clinical history in breast cancer treatment and a potentially more favorable side effect profile at standard doses.

Anastrozole 1 mg is the standard clinical dose for breast cancer treatment in postmenopausal women. In non-medical bodybuilding contexts, 1 mg is often considered a high dose for estrogen management, and lower doses or less frequent administration are commonly referenced to avoid excessive estrogen suppression.

Anastrozole 1 mg is labeled at 1 mg of anastrozole per tablet. It is supplied as oral tablets in packs of 50 or 100 tablets manufactured by British Dragon.

Yes. A published laboratory report dated March 23, 2026 measured Anastrozole 1 mg at 0.96 mg, equivalent to 96.00% of its 1 mg label claim. The complete report can be viewed in the Lab Reports tab.